JP2019523221A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523221A5
JP2019523221A5 JP2018561225A JP2018561225A JP2019523221A5 JP 2019523221 A5 JP2019523221 A5 JP 2019523221A5 JP 2018561225 A JP2018561225 A JP 2018561225A JP 2018561225 A JP2018561225 A JP 2018561225A JP 2019523221 A5 JP2019523221 A5 JP 2019523221A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
seq
antibody according
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018561225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523221A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/034681 external-priority patent/WO2017205742A1/en
Publication of JP2019523221A publication Critical patent/JP2019523221A/ja
Publication of JP2019523221A5 publication Critical patent/JP2019523221A5/ja
Priority to JP2022023569A priority Critical patent/JP7331179B2/ja
Withdrawn legal-status Critical Current

Links

JP2018561225A 2016-05-27 2017-05-26 抗ｃｄ４０抗体とその使用 Withdrawn JP2019523221A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022023569A JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662342417P 2016-05-27 2016-05-27
US62/342,417 2016-05-27
PCT/US2017/034681 WO2017205742A1 (en) 2016-05-27 2017-05-26 Anti-cd40 antibodies and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022023569A Division JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Publications (2)

Publication Number Publication Date
JP2019523221A JP2019523221A (ja) 2019-08-22
JP2019523221A5 true JP2019523221A5 (enExample) 2020-07-02

Family

ID=59014833

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561225A Withdrawn JP2019523221A (ja) 2016-05-27 2017-05-26 抗ｃｄ４０抗体とその使用
JP2022023569A Active JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022023569A Active JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Country Status (35)

Country Link
US (8) US10519243B2 (enExample)
EP (2) EP3995511A1 (enExample)
JP (2) JP2019523221A (enExample)
KR (2) KR20220028143A (enExample)
CN (1) CN109476750B (enExample)
AR (2) AR108611A1 (enExample)
AU (1) AU2017271602A1 (enExample)
BR (1) BR112018074468A2 (enExample)
CA (1) CA3025347A1 (enExample)
CL (1) CL2018003366A1 (enExample)
CO (1) CO2018012699A2 (enExample)
CR (1) CR20180605A (enExample)
CY (1) CY1124806T1 (enExample)
DO (1) DOP2018000258A (enExample)
EC (1) ECSP18094829A (enExample)
ES (1) ES2901722T3 (enExample)
HR (1) HRP20211882T1 (enExample)
HU (1) HUE056670T2 (enExample)
IL (1) IL263223B2 (enExample)
LT (1) LT3464361T (enExample)
MX (1) MX393455B (enExample)
MY (1) MY195442A (enExample)
NZ (1) NZ748644A (enExample)
PE (1) PE20190970A1 (enExample)
PH (1) PH12018502456A1 (enExample)
PL (1) PL3464361T3 (enExample)
PT (1) PT3464361T (enExample)
RS (1) RS62726B1 (enExample)
RU (1) RU2752049C2 (enExample)
SG (2) SG11201810522UA (enExample)
SI (1) SI3464361T1 (enExample)
SM (1) SMT202100721T1 (enExample)
TW (2) TWI814279B (enExample)
UA (1) UA123111C2 (enExample)
WO (1) WO2017205742A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3097926T3 (pl) * 2007-11-01 2020-04-30 The Board Of Trustees Of The University Of Arkansas Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria
AR108611A1 (es) * 2016-05-27 2018-09-05 Abbvie Biotherapeutics Inc Anticuerpos anti-cd40 y sus usos
KR20210005082A (ko) * 2018-04-20 2021-01-13 리브젠 바이오파마 코., 엘티디. 항-cd40 항체 및 이의 용도
EP3883600B1 (en) 2018-11-23 2025-03-12 Strike Pharma AB Bi-specific conjugates
BR112021009835A2 (pt) * 2018-11-30 2021-08-17 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
CN111454364B (zh) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 结合cd40的抗体及其用途
EP3947454A1 (en) 2019-03-27 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
CN113728008B (zh) * 2019-04-10 2024-04-09 南开大学 抗cd40抗体及其用途
GB201910900D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
KR20220062036A (ko) * 2019-09-11 2022-05-13 노파르티스 아게 환자에서 인간 바이러스 연관된 장애를 방지하는 방법
CA3158527A1 (en) * 2019-10-23 2021-04-29 Lyvgen Biopharma Holdings Limited Anti-cd40 binding molecules and bi-specific antibodies comprising such
CN115038718B (zh) * 2019-11-08 2024-07-02 山东先声生物制药有限公司 抗人程序性死亡配体-1（pd-l1）的抗体及其用途
IL293450A (en) * 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-associated antigen binding proteins and uses thereof
GB202008003D0 (en) * 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2022020109A1 (en) * 2020-07-23 2022-01-27 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
CN115403670B (zh) * 2021-05-26 2026-03-10 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
CA3257929A1 (en) * 2022-05-31 2025-04-22 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Anti-CD40 antibodies, bispecific anti-PD-L1×CD40 antibodies, and their use
WO2024059899A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Bispecific polypeptides and uses thereof
AR131856A1 (es) * 2023-02-16 2025-05-07 Sanofi Sa Proteínas de unión a cd40

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CN100490895C (zh) 2000-02-01 2009-05-27 泛遗传学公司 结合cd40的apc激活分子
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2397631T3 (es) 2003-12-25 2013-03-08 Kyowa Hakko Kirin Co., Ltd. Mutante antagonista de anticuerpos ANTI-CD40
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006017173A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AU2007294575B2 (en) * 2006-09-08 2013-06-27 Viela Bio, Inc. Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
BRPI0818621A8 (pt) * 2007-10-05 2018-01-30 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa e a quantidade de placas na camada de célula de gânglio retinal de um indivíduo, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular, para diagnosticar uma doença ocular e uma predisposição a uma doença ocular, para monitorar doença ocular, para predizer responsividade de um paciente, e para reter ou diminuir pressão ocular nos olhos de um indivíduo
PT3178851T (pt) * 2010-03-31 2020-07-17 Boehringer Ingelheim Int Anticorpos anti-cd40
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
TWI855488B (zh) * 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
CN104918957B (zh) * 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
CA2904528C (en) * 2013-03-15 2021-01-19 Abbvie Biotherapeutics Inc. Fc variants
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
PL3212230T3 (pl) 2014-10-29 2021-07-26 Seagen Inc. Dawkowanie i podawanie niefukozylowanych przeciwciał anty-CD40
RU2715597C2 (ru) * 2015-05-29 2020-03-02 Эббви Инк. Антитела к cd40 и способы их применения
AR108611A1 (es) * 2016-05-27 2018-09-05 Abbvie Biotherapeutics Inc Anticuerpos anti-cd40 y sus usos
SG11201810591VA (en) * 2016-05-27 2018-12-28 Abbvie Biotherapeutics Inc Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen

Similar Documents

Publication Publication Date Title
JP2019523221A5 (enExample)
JP2020504101A5 (enExample)
RU2018146533A (ru) Антитела к cd40 и пути их применения
JP2019533989A5 (ja) 抗ｐｄ−１抗体及びその使用
JP2012254092A5 (enExample)
JP2017114866A5 (enExample)
JP2018121657A5 (enExample)
JP2012116856A5 (enExample)
JP2018536393A5 (enExample)
JP2013538057A5 (enExample)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2019524645A5 (enExample)
JP2016511750A5 (enExample)
JP2015535828A5 (enExample)
JP2019527047A5 (enExample)
JP2018504105A5 (enExample)
RU2019110835A (ru) Антитела к pd-1(cd279)
JP2015146822A5 (enExample)
JP2014237714A5 (enExample)
JP2017522888A5 (enExample)
JP2021501744A5 (enExample)
HRP20201090T1 (hr) Protutijela anti-icos
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2012143232A5 (enExample)
JP2016185981A5 (enExample)